UConn Health
MS Changes the Microbiome Subtly but Similarly, Whether in US or Asia
Multiple sclerosis affects about a million people in the US, and millions more elsewhere in the world
Live Longer, Die Healthier
UConn researchers have demonstrated a treatment that could lengthen life—and vigor—up to the very end
Prestigious Scientific Honor Society Inducts UConn Health’s Neurosurgery Chief
Dr. Ketan Bulsara joins Sigma Xi, the world’s largest multidisciplinary honor society for scientists and engineers
Kindness, Pass it On
'Being kind can go a long way to improving someone else’s day,' says UConn Health IT Department’s Jon Gorman
When Multiple Sclerosis is Personal
Neuroscientist Stephen J. Crocker, Ph.D. of UConn School of Medicine and colleagues are on a hunt for a new treatment for MS
UConn Professor Cato T. Laurencin to Receive Sigma Xi Gold Key Award
On November 16 Dr. Cato T. Laurencin, University Professor and Albert and Wilda Van Dusen Distinguished Professor of Orthopaedic Surgery, will receive the Gold Key Award from the Sigma Xi Scientific Research Honor Society.
Dr. Ketan Bulsara Elected to Prominent Role for American Association Neurological Surgeons/Congress Neurological Surgeons Joint Section
Through a nationwide election, Dr. Ketan Bulsara, chief of the Division of Neurosurgery at UConn Health has been elected the 43rd chair of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Joint Section of Cerebrovascular Surgery.
The Cato T. Laurencin, M.D., Ph.D. Travel Fellowship Award at the World Biomaterials Congress in South Korea
Named in honor of a distinguished member of the Society for Biomaterials, the Cato T. Laurencin, M.D., Ph.D. Travel Fellowship supports underrepresented undergraduate students studying the field of biomaterials.
New York Institute of Technology Grants Professor Cato T. Laurencin Honorary Degree
As an honored guest of the 63rd commencement ceremony, Laurencin was also a guest speaker at the College of Osteopathic Medicine.
Alzheimer’s Drug Offers Hope for Early-Stage Patients
'This is the most promising medication we've had so far in terms of slowing rate of decline.'